These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 12402392)

  • 21. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification.
    Tsukamoto N; Kojima M; Hasegawa M; Oriuchi N; Matsushima T; Yokohama A; Saitoh T; Handa H; Endo K; Murakami H
    Cancer; 2007 Aug; 110(3):652-9. PubMed ID: 17582800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
    Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
    Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
    Spaepen K; Mortelmans L
    Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma.
    Moog F; Kotzerke J; Reske SN
    J Nucl Med; 1999 Sep; 40(9):1407-13. PubMed ID: 10492357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 18F-fluorodeoxyglucose-positron emission tomography in the staging of malignant lymphoma compared with CT and 67Ga scan.
    Hong SP; Hahn JS; Lee JD; Bae SW; Youn MJ
    Yonsei Med J; 2003 Oct; 44(5):779-86. PubMed ID: 14584092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
    Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas.
    Mikhaeel NG; Timothy AR; Hain SF; O'Doherty MJ
    Ann Oncol; 2000; 11 Suppl 1():147-50. PubMed ID: 10707798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma.
    Hernandez-Maraver D; Hernandez-Navarro F; Gomez-Leon N; Coya J; Rodriguez-Vigil B; Madero R; Pinilla I; Martin-Curto LM
    Br J Haematol; 2006 Nov; 135(3):293-302. PubMed ID: 17032175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment.
    Bar-Shalom R; Mor M; Yefremov N; Goldsmith SJ
    Semin Nucl Med; 2001 Jul; 31(3):177-90. PubMed ID: 11430525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PET scans in the staging of lymphoma: current status.
    Friedberg JW; Chengazi V
    Oncologist; 2003; 8(5):438-47. PubMed ID: 14530496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positron emission tomography in the evaluation of lymphoma.
    Israel O; Keidar Z; Bar-Shalom R
    Semin Nucl Med; 2004 Jul; 34(3):166-79. PubMed ID: 15202099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [F-18 fluorodeoxyglucose positron emission tomography in malignant lymphoma].
    Mikosch P
    Wien Med Wochenschr; 2002; 152(11-12):269-75. PubMed ID: 12138654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma].
    Thill R; Neuerburg J; Fabry U; Cremerius U; Wagenknecht G; Hellwig D; Osieka R; Günther R; Büll U
    Nuklearmedizin; 1997 Oct; 36(7):234-9. PubMed ID: 9441282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
    Even-Sapir E; Lievshitz G; Perry C; Herishanu Y; Lerman H; Metser U
    Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
    Kumar R; Xiu Y; Zhuang HM; Alavi A
    Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience.
    Tatsumi M; Cohade C; Nakamoto Y; Fishman EK; Wahl RL
    Radiology; 2005 Dec; 237(3):1038-45. PubMed ID: 16304117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical value of FDG PET for therapy monitoring of malignant lymphoma--results of a retrospective study in 72 patients].
    Cremerius U; Fabry U; Kröll U; Zimny M; Neuerburg J; Osieka R; Büll U
    Nuklearmedizin; 1999; 38(1):24-30. PubMed ID: 9987778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positron emission tomography and lymphoma therapy.
    Golder W
    Onkologie; 2001 Oct; 24(5):496-8. PubMed ID: 11694779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?
    Schaefer NG; Hany TF; Taverna C; Seifert B; Stumpe KD; von Schulthess GK; Goerres GW
    Radiology; 2004 Sep; 232(3):823-9. PubMed ID: 15273335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PET and PET/CT in management of the lymphomas.
    Podoloff DA; Macapinlac HA
    Radiol Clin North Am; 2007 Jul; 45(4):689-96, vii. PubMed ID: 17706533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.